

Enamine, Chemspace, and PharmAI Discovery Join Forces to Advance AI-Driven Drug Discovery for Novel Theranostics

DRESDEN, GERMANY, February 26, 2025 /EINPresswire.com/ -- Enamine, Chemspace, and PharmAI Discovery (PAID) start a transformative collaboration to accelerate the advancement of theranostics through AI-driven drug discovery with emphasis on cancer diagnosis and therapy. This collaboration brings together the success of Enamine's discovery biology and chemistry competencies, Chemspace's expertise in ultra-large chemical space exploration for drug discovery, and PAID's AI-powered molecular discovery platform to identify and develop promising drug candidates faster and with greater precision, both for conventional and molecular radiotherapy and radio diagnostics. Specific modulator molecules labeled with a radioisotope can target various cancers highly selective and locate such cancer cells for diagnosis or deliver precisely radiation for their destruction. The recent successes in radioligand therapy (RLT) in the clinic, regulatory breakthrough therapy designations, product approvals, and broad technology advancements catalyzed considerable growth in this field, evident by new company formations and market expansion. This partnership allows for the critical acceleration of the Design-Make-Test-Analyze cycle of potential compounds for RLT, saving time towards new treatments for cancer patients with still unmet medical needs.



"Our team is excited to be part of the first commercial partnership between a pharmaceutical company and a technology company. This partnership will allow us to leverage our expertise in drug discovery and our state-of-the-art technology to accelerate the development of new drugs. We are committed to providing our customers with the highest quality products and services, and we are confident that this partnership will be a successful one."

"This partnership is a significant milestone for our company, and we are proud to be part of this journey. We are committed to providing our customers with the highest quality products and services, and we are confident that this partnership will be a successful one. We are excited to see the results of this partnership and the new drugs that will be developed. We are committed to providing our customers with the highest quality products and services, and we are confident that this partnership will be a successful one."

Our team is excited to be part of the first commercial partnership between a pharmaceutical company and a technology company. This partnership will allow us to leverage our expertise in drug discovery and our state-of-the-art technology to accelerate the development of new drugs. We are committed to providing our customers with the highest quality products and services, and we are confident that this partnership will be a successful one.

Chemspace

Chemspace is a global provider of drug discovery services. We can streamline hit finding by integrating our Computational Chemistry tools, Bioinformatics, and Machine Learning-based services for smarter drug discovery. By exploring ultra-large chemical spaces, we deliver high-quality hit molecules for discovery projects. Our integrated projects combine hit identification services with biological validation, providing a seamless path from hit identification to pre-clinical studies.

For more information, visit <https://chem-space.com>

Enamine

Enamine is a scientifically driven integrated discovery Contract Research Organization with unique partnering opportunities in exploring chemical space. The company combines access to the in-house produced screening compounds (4.4M in stock) and building blocks (300K in stock) with a comprehensive platform of integrated discovery services, including discovery biology, to advance and accelerate the efforts in drug discovery.

For more information, visit <https://enamine.net>

PharmAI Discovery GmbH, based in Dresden, Germany, is an innovative biotechnology company specializing in both AI-driven drug discovery and drug development. PharmAI Discovery accelerates the identification, optimization, and clinical translation of novel therapeutics by combining cutting-edge artificial intelligence with experimental validation.

For more information, visit <https://pharmai-discovery.com>

Olga Tarkhanova, Ph.D.
Email: o.tarkhanova@chem-space.com
<https://chem-space.com>

Yurii Moroz, Ph.D.
Email: yurii.moroz@enamine.net
<https://enamine.net>

Mahmood Nazari, Ph.D.
Email: info@pharmai-discovery.com
<https://pharmai-discovery.com>

Yurii Moroz, Ph.D.
Enamine Ltd.
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/789023089>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.